Zonegran® (Zonisamide) Monotherapy Now Available in Russia for Adults With Newly Diagnosed Epilepsy

  Zonegran® (Zonisamide) Monotherapy Now Available in Russia for Adults With                            Newly Diagnosed Epilepsy    PR Newswire    HATFIELD, England, April 28, 2014  HATFIELD, England, April 28, 2014 /PRNewswire/ --  Zonegran ^® (zonisamide) is now available in Russia as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. ^[1] Once-daily zonisamide is a second generation anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AEDs. ^[ ^1 ^]  For people with newly diagnosed epilepsy, monotherapy is the preferred option for managing their condition as the potential for adverse drug interactions is reduced and treatment compliance is encouraged. ^[2]  "Monotherapy is the optimal treatment approach for newly diagnosed epilepsy and zonisamide's proven efficacy in this setting will help people to control their seizures," commented Professor Pavel Vlasov, Neurology and Neurosurgery department at the Moscow State University of Medicine and Stomatology."Zonisamide is a welcome new addition to our armamentarium in Russia."  Epilepsy is one of the most common neurological conditions in the world. ^[3] Around 3 out of every 1,000 people in Russia live with the condition, 82% of which have partial epilepsy. ^[4] The successful treatment of partial onset seizures (the most common type of epilepsy) remains a significant challenge and up to 30% of patients fail to achieve seizure freedom with existing AEDs. ^[5]  The efficacy and safety of zonisamide as monotherapy has been demonstrated in a double-blind, randomised, multicentre study of 583 newly diagnosed adult partial epilepsy patients, which compared the efficacy and safety of once-daily zonisamide with twice-daily controlled release carbamazepine as monotherapy. The study's primary endpoint was the proportion of seizure-free patients for 26 weeks or more. Zonisamidedemonstrated high seizure freedom rates in newly diagnosed patients with epilepsy, ^[ ^6] similar to controlled release carbamazepine. In the majority of patients, seizure freedom was achieved at the target dose of 300 mg. Zonisamide was considered non-inferior to carbamazepine andwas well tolerated after one year of treatment at doses ranging from 300 to 500 mg/day.  "We are delighted to announce the launch of Zonegran in Russia." commended Olga Konopleva, Managing Director, Eisai Russia. "Patients are our first priority and we hope that the availability of Zonegran monotherapy provides doctors with a new alternative treatment option that allows them to tailor treatment to individual patient needs."  The continued development of zonisamide underscores Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide. Eisai is committed to the therapeutic area of epilepsy and addressing the unmet medical needs of people with epilepsy and their families. Eisai is proud to market currently more epilepsy products in EMEA than any other company.                                   ***ENDS***   Notes to Editors   About Zonegran (zonisamide)   Zonisamide is licensed in Europe as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. Zonisamide is also indicated in Europe as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents and children aged six years and above. ^[ ^1 ^] It has a broad spectrum of anti-epileptic modes of action and has no appreciable effects on steady-state plasma concentrations of other AEDs, such as phenytoin, carbamazepine and valproate. ^[ ^1 ^] Zonegran is one of only four AEDs with level A efficacy/effectiveness evidence as initial monotherapy for adults with partial onset seizures. ^[7] ^ Worldwide there has been an estimated 1,274,963 patient-years of exposure to Zonegran® (from 31.03.1989 to 31.03.2013). ^[8]  Zonisamide is available in 25mg, 50mg, and 100mg capsule strengths. The recommended daily dose for monotherapy use is 100mg once daily. In the third and fourth weeks the dose may be increased to 200mg daily and then increased to 300mg daily after the next two weeks.The recommended initial daily dose for adjunctive use is 50mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. ^[ ^1 ^]  For further information please visit: http://www.zonegran.eu  About Epilepsy   Epilepsy is one of the most common neurological conditions in the world, affecting approximately eight in 1,000 people in Europe, and an estimated 50 million people worldwide. ^[9] ^, ^[10] Epilepsy is a chronic disorder of the brain that affects people of all ages. It is characterised by abnormal discharges of neuronal activity causing seizures. Seizures can vary in severity, from brief lapses of attention or jerking of muscles, to severe and prolonged convulsions. Depending on the seizure type, seizures may be limited to one part of the body, or may involve the whole body. Seizures can also vary in frequency from less than one per year, to several per day. Epilepsy has many possible causes but often the cause is unknown.  About Eisai EMEA in Epilepsy   Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic area for Eisai in Europe, the Middle East, Africa, Russia and Oceania (EMEA).  In the EMEA region, Eisai currently has four marketed treatments including:    *Fycompa ^® (perampanel) for use as an adjunctive treatment for partial     onset seizures, with or without secondarily generalised seizures, in     patients with epilepsy aged 12 years and older   *Zonegran ^® (zonisamide) as monotherapy in adults in the treatment of     partial seizures, with or without secondary generalisation, in adults with     newly diagnosed epilepsy and as adjunctive therapy in the treatment of     partial seizures, with or without generalisation, in adults, adolescents     and children aged six years and above. (Zonegran is under license from the     originator Dainippon Sumitomo Pharma)   *Zebinix ^® (eslicarbazepine acetate) as adjunctive therapy in adult     patients with partial onset seizures, with or without secondary     generalisation. (Zebinix is under license from BIAL)   *Inovelon ^® (rufinamide) for the adjunctive treatment of seizures     associated with Lennox-Gastaut Syndrome in patients ≥4 years (Rufinamide     was originally developed by Novartis)  About Eisai   Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care ( hhc ).  Eisai concentrates its R&D activities in three key areas:    *Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight     loss   *Oncology including: anticancer therapies; tumour regression, tumour     suppression, antibodies, etc.   *Vascular/Immunological reaction including: thrombocytopenia, rheumatoid     arthritis, psoriasis, inflammatory bowel disease  With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, Russia and the Middle East.  For further information please visit our web site http://www.eisai.ru or http://www.eisai.co.uk  References   1. Eisai Ltd 2013. Zonegran summary of product characteristics (last updated October 2013) https://www.medicines.org.uk/emc/history/16240/SPC/Zonegran+25,+50,+100+mg+Hard+Capsules   2. St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management (2009) &(2): 77-72  3. ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe 2010. Available at; http://www.ilae.org/Visitors/Documents/ILAEAnnual-Report2010Final_000.pdf (Accessed September 2013)   4. Guekht A. et al. The epidemiology of epilepsy in the Russian Federation. Epilepsy Res 2010; 92(2-3):209-18   5. Kwan P, Brodie MJ Early identification of refractory epilepsy. New England Journal of Medicine 2000; 342:314-9  6. Baulac, M. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 11 (7) 579 - 588  7. Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.  8. Data on file: ZON2013-0003. Eisai Europe Ltd.  9. Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe. http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510.pdf [ http://www.ibe-epilepsy.org/downloads/EURO Report 160510.pdf ] [Accessed September 2013].  10. Pugliatti M, et al. Epilepsia 2007: 48(12) 2224-2233.  Date of preparation: April 2014  Job code: Zonegran-UK2520  Contact: Media Enquiries: Eisai Europe Ltd, Cressida Robson / Charlotte Andrews, +44(0)7908-314-155/+44(0)7947-231-513, Cressida_Robson@eisai.net, Charlotte_Andrews@eisai.net. Tonic Life Communications, Frances Murphy/Nicola Lilley , +44(0)207-798-9262 /+44-(0)207-798-9905, frances.murphy@toniclc.com, nicola.lilley@toniclc.com